PEAK6’s BioMarin Pharmaceuticals BMRN Stock Holding History

PEAK6’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,300	Closed	-$315K	–	2732
2025 Q4	$315K	Hold	5,300	–	–	﹤0.01%	2264
2025 Q3	$287K	Sell	5,300 -313,600	-98%	-$17.9M	﹤0.01%	2350
2025 Q2	$17.5M	Buy	+318,900	New	+$18.8M	0.03%	418
2025 Q1	–	Sell	-2,000	Closed	-$131K	–	3033
2024 Q4	$131K	Buy	+2,000	New	+$134K	﹤0.01%	2660

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6's BMRN Position: Q3 2025 in Review

PEAK6 sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 35,005 shares — an estimated $2M sold.

PEAK6 first reported a position in BMRN in Q4 2024 and held it in 2 quarters. The position peaked at $1.92M in Q2 2025. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

PEAK6 reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
PEAK6 sold 35,005 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $2M.
PEAK6 first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 2 quarters.
PEAK6's BioMarin Pharmaceuticals position peaked at $1.92M in Q2 2025.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.